ABCA3 p.Asn568Asp
ClinVar: |
c.1702A>G
,
p.Asn568Asp
D
, Pathogenic
|
Predicted by SNAP2: | A: D (66%), C: D (66%), D: N (53%), E: N (53%), F: D (75%), G: D (53%), H: N (57%), I: D (66%), K: N (61%), L: D (71%), M: D (71%), P: D (66%), Q: N (53%), R: N (57%), S: N (66%), T: N (61%), V: D (63%), W: D (91%), Y: D (75%), |
Predicted by PROVEAN: | A: D, C: D, D: D, E: D, F: D, G: D, H: D, I: D, K: D, L: D, M: D, P: D, Q: D, R: D, S: D, T: D, V: D, W: D, Y: D, |
[switch to compact view]
Comments [show]
None has been submitted yet.
[hide] A novel conserved targeting motif found in ABCA tr... J Lipid Res. 2011 Aug;52(8):1471-82. Epub 2011 May 17. Beers MF, Hawkins A, Shuman H, Zhao M, Newitt JL, Maguire JA, Ding W, Mulugeta S
A novel conserved targeting motif found in ABCA transporters mediates trafficking to early post-Golgi compartments.
J Lipid Res. 2011 Aug;52(8):1471-82. Epub 2011 May 17., [PMID:21586796]
Abstract [show]
The ATP binding cassette, class A (ABCA) proteins are homologous polytopic transmembrane transporters that function as lipid pumps at distinct subcellular sites in a variety of cells. Located within the N terminus of these transporters, there exists a highly conserved xLxxKN motif of unknown function. To define its role, human ABCA3 was employed as a primary model representing ABCA transporters, while mouse ABCA1 was utilized to support major findings. Transfection studies showed colocalization of both transporters with surfactant protein C (SP-C), a marker peptide for successful protein targeting to lysosomal-like organelles. In contrast, alanine mutation of xLxxKN resulted in endoplasmic reticulum retention. As proof of principle, swapping xLxxKN for the known lysosomal targeting motif of SP-C resulted in post-Golgi targeting of the SP-C chimera. However, these products failed to reach their terminal processing compartments, suggesting that the xLxxKN motif only serves as a Golgi exit signal. We propose a model whereby an N-terminal signal sequence, xLxxKN, directs ABCA transporters to a post-Golgi vesicular sorting station where additional signals may be required for selective delivery of individual transporters to final subcellular destinations.
Comments [show]
None has been submitted yet.
No. Sentence Comment
167 Most prominent of these was L101P, which, when transfected into similar cell lines, produced profound ER retention.
X
ABCA3 p.Asn568Asp 21586796:167:56
status: NEW168 In addition to this trafficking mutant, another mutant, N568D, was in fact trafficked to lysosomes but failed to concentrate NBD-phosphaty- dilcholine in this compartment.
X
ABCA3 p.Asn568Asp 21586796:168:56
status: NEW[hide] ABCA3 gene mutations in newborns with fatal surfac... N Engl J Med. 2004 Mar 25;350(13):1296-303. Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M
ABCA3 gene mutations in newborns with fatal surfactant deficiency.
N Engl J Med. 2004 Mar 25;350(13):1296-303., [PMID:15044640]
Abstract [show]
BACKGROUND: Pulmonary surfactant forms a lipid-rich monolayer that coats the airways of the lung and is essential for proper inflation and function of the lung. Surfactant is produced by alveolar type II cells, stored intracellularly in organelles known as lamellar bodies, and secreted by exocytosis. The gene for ATP-binding cassette transporter A3 (ABCA3) is expressed in alveolar type II cells, and the protein is localized to lamellar bodies, suggesting that it has an important role in surfactant metabolism. METHODS: We sequenced each of the coding exons of the ABCA3 gene in blood DNA from 21 racially and ethnically diverse infants with severe neonatal surfactant deficiency for which the etiologic process was unknown. Lung tissue from four patients was examined by high-resolution light and electron microscopy. RESULTS: Nonsense and frameshift mutations, as well as mutations in highly conserved residues and in splice sites of the ABCA3 gene were identified in 16 of the 21 patients (76 percent). In five consanguineous families with mutations, each pair of siblings was homozygous for the same mutation and each mutation was found in only one family. Markedly abnormal lamellar bodies were observed by ultrastructural examination of lung tissue from four patients with different ABCA3 mutations, including nonsense, splice-site, and missense mutations. CONCLUSIONS: Mutation of the ABCA3 gene causes fatal surfactant deficiency in newborns. ABCA3 is critical for the proper formation of lamellar bodies and surfactant function and may also be important for lung function in other pulmonary diseases. Since it is closely related to ABCA1 and ABCA4, proteins that transport phospholipids in macrophages and photoreceptor cells, it may have a role in surfactant phospholipid metabolism.
Comments [show]
None has been submitted yet.
No. Sentence Comment
44 Family History/ Consanguinity Outcome Histologic Findings ABCA3 Mutation 1 White F 1 Yes/Yes Death within 3 mo after birth DIP, PAP W1142X/W1142X 2 White F 1 Yes/Yes Death during neonatal period DIP, PAP W1142X/W1142X 3 Black M 2 Yes/Yes Death during neonatal period NA L101P/L101P 4 Black M 2 Yes/Yes Death during neonatal period NA L101P/L101P 5 White F 3 Yes/No Death during neonatal period NA 4552insT/L1580P 6 White F 3 Yes/No Death during neonatal period NA 4552insT/L1580P 7 White M 4 Yes/No Death within 3 mo after birth PAP G1221S/L982P 8 White M 4 Yes/No Death during neonatal period PAP G1221S/L982P 9 Middle Eastern M 5 Yes/Yes Death during neonatal period DIP, PAP L1553P/L1553P 10 Middle Eastern M 5 Yes/Yes Death during neonatal period NA L1553P/L1553P 11 White M 6 Yes/No Recovery from RDS NA None found 12 White M 6 Yes/No Recovery from RDS NA None found 13 Middle Eastern M 7 No/Yes Unknown NA 1644delC/1644delC 14 Middle Eastern M 8 Yes/No Death during neonatal period DIP, PAP R106X/R106X 15 Asian F 9† Yes/Yes Death during neonatal period NA 4909+1G>A/4909+1G>A 16 White M 10 Yes/Yes Death during neonatal period NA None found 17 White M 11 No/No Recovery from RDS NA None found 18 White F 12 No/No Death during neonatal period NA None found 19 White M 13 Yes/No Chronic lung disease CPI, DIP Q1591P/-‡ 20 Hispanic M 14 No/No Death after lung transplantation PAP N568D/-‡ 21 Asian F 9† Yes/Yes Death during neonatal period PAP 4909+1G>A/4909+1G>A entorganisms,weusedthededucedaminoacidse- quence of ABCA3 (GenBank accession number NP_001080) to search the sequence data base using the BLAST program (http://www.ncbi.nlm.nih.
X
ABCA3 p.Asn568Asp 15044640:44:1396
status: NEW59 Seven missense muta- tionswereidentifiedinconservedaminoacids(Fig. 2), including homozygous substitutions of proline for leucine in codons 101 and 1553 (L101P and L1553P, respectively) and heterozygous substitutions of aspartic acid for asparagine at position 568 (N568D), proline for leucine at position 982 (L982P), serine for glycine at position 1221 (G1221S), proline for leucine at position 1580 (L1580P), and proline for glutamine at position 1591 (Q1591P).
X
ABCA3 p.Asn568Asp 15044640:59:219
status: NEWX
ABCA3 p.Asn568Asp 15044640:59:265
status: NEW87 Human Mouse Rat Puffer fish ETVRRALVIN ETVKREFMIK EAVRREFMIK EDVRGKLELS QDVQQNLVRG L101P NGAGKTT NGAGKTT NGAGKTT NGAGKTT NGAGKTT N568D VARRLL VARRLL VARRLL VARRLL L1553P Q1591P T301C(L101P) C316T(R106X) A1702G(N568D) 1644delC G3426A(W1142X) G3661A(G1221S) T4657C(L1553P) 4552insT A4771C(Q1591P) 4909+1G>A G1221S LSGIAT LSGIAT LSGIAT ATP-binding domains L982P QQLSEHL QQLSENL QQLSEHL T2945C(L982P) ECEALC LAIMVQGQFKC ECEALC ECEALC L1580P T4739C(L1580P) Nonsense MissenseSpliceFrameshift LAIMVQGQFKC LAIMVQGQFKC LAVMVNGQFKC Zebra fish LAVMVNGQFKC tified occur in residues that are highly conserved (Fig.2).Theaminoacidalignmentwasusedtopro- duce a phylogenetic tree of the ABCA3-related proteins showing the relation of the proteins from different organisms (see Supplementary Appendix 2, available with the full text of this article at www. nejm.org).ThefishABCA3proteinsclusterwiththe mammalian ABCA3 proteins and are distinct from other, more distant ABCA-family proteins, such as the mouse Abca14, Abca15, and Abca16 proteins and the sea-urchin ABCA proteins (see Supplementary Appendix 2.
X
ABCA3 p.Asn568Asp 15044640:87:129
status: NEWX
ABCA3 p.Asn568Asp 15044640:87:210
status: NEW97 In the case of the L101P and L1553P mutations, each of which affected one pair of siblings from two different families, the two pairs of siblings were both homozygous for the variant and homozygous for all other polymorphisms that we found in the gene - findings that are consistent with the occurrence of a recessive mutation in these consanguineous families.
X
ABCA3 p.Asn568Asp 15044640:97:4
status: NEW98 The N568D mutation is in a highly conserved residue in the ATP-binding domain, and it almost certainly disrupts the function of the protein.
X
ABCA3 p.Asn568Asp 15044640:98:4
status: NEW106 Nucleotide Affected* Site Affected or Outcome SNP No.† Mutation Exon 5 3, 4 T301C L101P‡ Exon 5 14 C316T R106X‡ Exon 14 20 A1702G N568D Exon 14 13 1644delC Frameshift‡ Exon 21 7, 8 T2945C L982P Exon 23 1, 2 G3426A W1142X‡ Exon 24 7, 8 G3661A G1221S Exon 30 9, 10 T4657C L1553P Exon 30 5, 6 4552insT Frameshift Exon 31 15, 21 4909+1G>A Splice site‡ Exon 31 5, 6 T4739C L1580P Exon 31 19 A4772C Q1591P Polymorphism Exon 5 Multiple Exon 5+50A/G Intron rs46725 Exon 6 20 393C/T A131A Exon 6 18 Exon 6+119G/A Intron rs323059 Exon 7 19 Exon 7-14C/G Intron Exon 8 14 681C/T A227A Exon 10 Multiple Exon 10-105C/A Intron rs323066 Exon 10 Multiple Exon 10-20C/T Intron Exon 10 Multiple 1058C/T F353F Exon 14 Multiple Exon 14+33G/A Intron rs170447 Exon 15 Multiple 1755C/G P585P rs323043 Exon 18 13 Exon 18-17G/A Intron Exon 18 1 2340C/T H780H Exon 21 Multiple Exon 21-20C/G Intron rs313908 Exon 21 Multiple Exon 21+34C/T Intron rs313909 Exon 27 Multiple 4116C/T S1372S rs149532 Exon 32 11 4944C/T V1648V In two patients, a mutation was identified on only one allele.
X
ABCA3 p.Asn568Asp 15044640:106:148
status: NEW43 Family History/ Consanguinity Outcome Histologic Findings ABCA3 Mutation 1 White F 1 Yes/Yes Death within 3 mo after birth DIP, PAP W1142X/W1142X 2 White F 1 Yes/Yes Death during neonatal period DIP, PAP W1142X/W1142X 3 Black M 2 Yes/Yes Death during neonatal period NA L101P/L101P 4 Black M 2 Yes/Yes Death during neonatal period NA L101P/L101P 5 White F 3 Yes/No Death during neonatal period NA 4552insT/L1580P 6 White F 3 Yes/No Death during neonatal period NA 4552insT/L1580P 7 White M 4 Yes/No Death within 3 mo after birth PAP G1221S/L982P 8 White M 4 Yes/No Death during neonatal period PAP G1221S/L982P 9 Middle Eastern M 5 Yes/Yes Death during neonatal period DIP, PAP L1553P/L1553P 10 Middle Eastern M 5 Yes/Yes Death during neonatal period NA L1553P/L1553P 11 White M 6 Yes/No Recovery from RDS NA None found 12 White M 6 Yes/No Recovery from RDS NA None found 13 Middle Eastern M 7 No/Yes Unknown NA 1644delC/1644delC 14 Middle Eastern M 8 Yes/No Death during neonatal period DIP, PAP R106X/R106X 15 Asian F 9ߤ Yes/Yes Death during neonatal period NA 4909+1G>A/4909+1G>A 16 White M 10 Yes/Yes Death during neonatal period NA None found 17 White M 11 No/No Recovery from RDS NA None found 18 White F 12 No/No Death during neonatal period NA None found 19 White M 13 Yes/No Chronic lung disease CPI, DIP Q1591P/-ߥ 20 Hispanic M 14 No/No Death after lung transplantation PAP N568D/-ߥ 21 Asian F 9ߤ Yes/Yes Death during neonatal period PAP 4909+1G>A/4909+1G>A entorganisms,weusedthededucedaminoacidse- quence of ABCA3 (GenBank accession number NP_001080) to search the sequence data base using the BLAST program (http://www.ncbi.nlm.nih.
X
ABCA3 p.Asn568Asp 15044640:43:1396
status: NEW58 Seven missense muta- tionswereidentifiedinconservedaminoacids(Fig. 2), including homozygous substitutions of proline for leucine in codons 101 and 1553 (L101P and L1553P, respectively) and heterozygous substitutions of aspartic acid for asparagine at position 568 (N568D), proline for leucine at position 982 (L982P), serine for glycine at position 1221 (G1221S), proline for leucine at position 1580 (L1580P), and proline for glutamine at position 1591 (Q1591P).
X
ABCA3 p.Asn568Asp 15044640:58:219
status: NEWX
ABCA3 p.Asn568Asp 15044640:58:265
status: NEW86 Human Mouse Rat Puffer fish ETVRRALVIN ETVKREFMIK EAVRREFMIK EDVRGKLELS QDVQQNLVRG L101P NGAGKTT NGAGKTT NGAGKTT NGAGKTT NGAGKTT N568D VARRLL VARRLL VARRLL VARRLL L1553P Q1591P T301C(L101P) C316T(R106X) A1702G(N568D) 1644delC G3426A(W1142X) G3661A(G1221S) T4657C(L1553P) 4552insT A4771C(Q1591P) 4909+1G>A G1221S LSGIAT LSGIAT LSGIAT ATP-binding domains L982P QQLSEHL QQLSENL QQLSEHL T2945C(L982P) ECEALC LAIMVQGQFKC ECEALC ECEALC L1580P T4739C(L1580P) Nonsense Missense Splice Frameshift LAIMVQGQFKC LAIMVQGQFKC LAVMVNGQFKC Zebra fish LAVMVNGQFKC tified occur in residues that are highly conserved (Fig.2).Theaminoacidalignmentwasusedtopro- duce a phylogenetic tree of the ABCA3-related proteins showing the relation of the proteins from different organisms (see Supplementary Appendix 2, available with the full text of this article at www. nejm.org).ThefishABCA3proteinsclusterwiththe mammalian ABCA3 proteins and are distinct from other, more distant ABCA-family proteins, such as the mouse Abca14, Abca15, and Abca16 proteins and the sea-urchin ABCA proteins (see Supplementary Appendix 2.
X
ABCA3 p.Asn568Asp 15044640:86:129
status: NEWX
ABCA3 p.Asn568Asp 15044640:86:210
status: NEW105 Nucleotide Affected* Site Affected or Outcome SNP No.ߤ Mutation Exon 5 3, 4 T301C L101Pߥ Exon 5 14 C316T R106Xߥ Exon 14 20 A1702G N568D Exon 14 13 1644delC Frameshiftߥ Exon 21 7, 8 T2945C L982P Exon 23 1, 2 G3426A W1142Xߥ Exon 24 7, 8 G3661A G1221S Exon 30 9, 10 T4657C L1553P Exon 30 5, 6 4552insT Frameshift Exon 31 15, 21 4909+1G>A Splice siteߥ Exon 31 5, 6 T4739C L1580P Exon 31 19 A4772C Q1591P Polymorphism Exon 5 Multiple Exon 5+50A/G Intron rs46725 Exon 6 20 393C/T A131A Exon 6 18 Exon 6+119G/A Intron rs323059 Exon 7 19 Exon 7-14C/G Intron Exon 8 14 681C/T A227A Exon 10 Multiple Exon 10-105C/A Intron rs323066 Exon 10 Multiple Exon 10-20C/T Intron Exon 10 Multiple 1058C/T F353F Exon 14 Multiple Exon 14+33G/A Intron rs170447 Exon 15 Multiple 1755C/G P585P rs323043 Exon 18 13 Exon 18-17G/A Intron Exon 18 1 2340C/T H780H Exon 21 Multiple Exon 21-20C/G Intron rs313908 Exon 21 Multiple Exon 21+34C/T Intron rs313909 Exon 27 Multiple 4116C/T S1372S rs149532 Exon 32 11 4944C/T V1648V In two patients, a mutation was identified on only one allele.
X
ABCA3 p.Asn568Asp 15044640:105:148
status: NEW[hide] Exosomal evasion of humoral immunotherapy in aggre... Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15336-41. Epub 2011 Aug 25. Aung T, Chapuy B, Vogel D, Wenzel D, Oppermann M, Lahmann M, Weinhage T, Menck K, Hupfeld T, Koch R, Trumper L, Wulf GG
Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3.
Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15336-41. Epub 2011 Aug 25., [PMID:21873242]
Abstract [show]
Targeting the surface of malignant cells has evolved into a cornerstone in cancer therapy, paradigmatically introduced by the success of humoral immunotherapy against CD20 in malignant lymphoma. However, tumor cell susceptibility to immunochemotherapy varies, with mostly a fatal outcome in cases of resistant disease. Here, we show that lymphoma exosomes shield target cells from antibody attack and that exosome biogenesis is modulated by the lysosome-related organelle-associated ATP-binding cassette (ABC) transporter A3 (ABCA3). B-cell lymphoma cells released exosomes that carried CD20, bound therapeutic anti-CD20 antibodies, consumed complement, and protected target cells from antibody attack. ABCA3, previously shown to mediate resistance to chemotherapy, was critical for the amounts of exosomes released, and both pharmacological blockade and the silencing of ABCA3 enhanced susceptibility of target cells to antibody-mediated lysis. Mechanisms of cancer cell resistance to drugs and antibodies are linked in an ABCA3-dependent pathway of exosome secretion.
Comments [show]
None has been submitted yet.
No. Sentence Comment
96 As a control, enforced expression of a nonfunctional ABCA3 mutated in the ATP-binding site (N568D) was not sufficient to induce such effects (Fig. 6 D-F) (16).
X
ABCA3 p.Asn568Asp 21873242:96:92
status: NEW163 To analyze ABCA3 function in exosome release, both silencing of ABCA3 with two independent shABCA3 constructs (PLKO.1-shRNA.38 and .39) and enforced gene expression with an ABCA3 wild-type plasmid and a nonfunctional mutant (pABCA3 N568D) were applied.
X
ABCA3 p.Asn568Asp 21873242:163:232
status: NEW92 As a control, enforced expression of a nonfunctional ABCA3 mutated in the ATP-binding site (N568D) was not sufficient to induce such effects (Fig. 6 D-F) (16).
X
ABCA3 p.Asn568Asp 21873242:92:92
status: NEW159 To analyze ABCA3 function in exosome release, both silencing of ABCA3 with two independent shABCA3 constructs (PLKO.1-shRNA.38 and .39) and enforced gene expression with an ABCA3 wild-type plasmid and a nonfunctional mutant (pABCA3 N568D) were applied.
X
ABCA3 p.Asn568Asp 21873242:159:232
status: NEW[hide] Identification and characterization of a novel ABC... Physiol Genomics. 2010 Jan 8;40(2):94-9. Epub 2009 Oct 27. Park SK, Amos L, Rao A, Quasney MW, Matsumura Y, Inagaki N, Dahmer MK
Identification and characterization of a novel ABCA3 mutation.
Physiol Genomics. 2010 Jan 8;40(2):94-9. Epub 2009 Oct 27., [PMID:19861431]
Abstract [show]
Mutations in the gene coding for ATP-binding cassette protein A3 (ABCA3) are recognized as a genetic cause of lung disease of varying severity. Characterization of a number of mutant ABCA3 proteins has demonstrated that the mutations generally affect intracellular localization or the ability of the protein to hydrolyze ATP. A novel heterozygous mutation that results in the substitution of cysteine for arginine at amino acid 295 in ABCA3 was identified in a premature infant with chronic respiratory insufficiency and abnormal lamellar bodies. Sequencing of DNA performed in study participants demonstrated that this was a mutation and not a common variant. Plasmid vectors containing ABCA3 with the identified novel mutation tagged with green fluorescent protein on the carboxy terminus were generated. The effect of the mutation on protein function was characterized by examining the glycosylation state of the mutant protein in transiently transfected HEK293 cells and by examining ATP hydrolysis activity of the mutant protein with a vanadate-induced nucleotide trapping assay in stably transfected HEK293 cells. The ABCA3 protein containing the R295C mutation undergoes normal glycosylation and intracellular localization but has dramatically reduced ATP hydrolysis activity (12% of wild type). The identification of one copy of this novel mutation in a premature infant with chronic respiratory insufficiency suggests that ABCA3 haploinsufficiency together with lung prematurity may result in more severe, or more prolonged, respiratory failure.
Comments [show]
None has been submitted yet.
No. Sentence Comment
53 Transient transfections of HEK293 cells with wild-type ABCA3-GFP and ABCA3 mutants L101P-GFP, N568D-GFP, and L982P-GFP (14), as well as the new pEGFPN1 construct for R295C-GFP, were performed with FuGENE 6 transfection reagent (Roche Applied Science, Indianapolis, IN) as previously described (14).
X
ABCA3 p.Asn568Asp 19861431:53:94
status: NEW99 Type I mutations include L101P, L982P, L1553P, and Q1591P; type II mutations include E292V, N568D, E690K, T1114, G1221S, and L1580P (13, 14).
X
ABCA3 p.Asn568Asp 19861431:99:92
status: NEW100 B: alignment of sequences surrounding the R295C mutation in ICL-1 in various members of the ABCA subfamily.
X
ABCA3 p.Asn568Asp 19861431:100:28
status: NEW105 As reported previously, the N568D variant shows resistance to Endo H (Fig. 3A, lanes 8 and 9) at a level similar to that of the wild-type protein; however, the L101P and L982P variants (Fig. 3A, lanes 4 and 5 and lanes 10 and 11, respectively) show no Endo H resistance, indicating that these mutants have not left the endoplasmic reticulum (14).
X
ABCA3 p.Asn568Asp 19861431:105:28
status: NEW110 The level of the ABCA3-R295C-GFP mutant protein was comparable to that of wild-type ABCA3-GFP as demonstrated in the anti-GFP immunoblot.
X
ABCA3 p.Asn568Asp 19861431:110:94
status: NEW111 Vanadate-induced nucleotide trapping was also decreased in the N568D mutant as reported previously (14).
X
ABCA3 p.Asn568Asp 19861431:111:63
status: NEW114 DISCUSSION The results presented here demonstrate that R295C is a novel mutation that results in severely impaired ATP hydrolysis activity as indicated by the dramatic reduction in vanadate-induced nucleotide trapping.
X
ABCA3 p.Asn568Asp 19861431:114:164
status: NEW115 Other mutations in the ABCA3 protein also result in impaired ATP hydrolysis, including E292V, N568D, G1221S, L1580P, and T1114M (13, 14).
X
ABCA3 p.Asn568Asp 19861431:115:94
status: NEW119 A: 20 g of membrane fraction from untransfected HEK293 cells (lanes 1 and 2), HEK293 cells stably expressing WT ABCA3-GFP (lanes 3 and 4), ABCA3-GFP mutants N568D (lanes 5 and 6), and R295C (lanes 7 and 8) were incubated with 20 M 8-azido-[␣-32 P]ATP in the absence (-) or presence (ϩ) of 0.4 mM orthovanadate (Vi) and 3 mM MgCl2 as described under MATERIALS AND METHODS.
X
ABCA3 p.Asn568Asp 19861431:119:165
status: NEW126 A: 20 g of membrane fraction from HEK293 cells transiently transfected with WT ABCA3-GFP (lanes 2 and 3) or with ABCA3-GFP mutants L101P (lanes 4 and 5), R295C (lanes 6 and 7), N568D (lanes 8 and 9), and L982P (lanes 10 and 11) were treated without (-) or with (ϩ) endoglycosidase H (Endo H) and analyzed by 5% SDS-PAGE followed by immunoblotting with anti-GFP antibody. Lane 1, immunoblotting of untransfected HEK293 cells.
X
ABCA3 p.Asn568Asp 19861431:126:185
status: NEW127 B: WT ABCA3-GFP (lanes 2 and 3) or ABCA3-GFP mutants L101P (lanes 4 and 5), R295C (lanes 6 and 7), N568D (lanes 8 and 9), and L982P (lanes 10 and 11) were treated without (-) or with (ϩ) peptide N-glycosidase F (PNGase F) and were then analyzed by 5% SDS-PAGE followed by immunoblotting with anti-GFP antibody. Lane 1, immunoblotting of untransfected HEK293 cells.
X
ABCA3 p.Asn568Asp 19861431:127:99
status: NEW48 Transient transfections of HEK293 cells with wild-type ABCA3-GFP and ABCA3 mutants L101P-GFP, N568D-GFP, and L982P-GFP (14), as well as the new pEGFPN1 construct for R295C-GFP, were performed with FuGENE 6 transfection reagent (Roche Applied Science, Indianapolis, IN) as previously described (14).
X
ABCA3 p.Asn568Asp 19861431:48:94
status: NEW94 Type I mutations include L101P, L982P, L1553P, and Q1591P; type II mutations include E292V, N568D, E690K, T1114, G1221S, and L1580P (13, 14).
X
ABCA3 p.Asn568Asp 19861431:94:92
status: NEW106 Vanadate-induced nucleotide trapping was also decreased in the N568D mutant as reported previously (14).
X
ABCA3 p.Asn568Asp 19861431:106:63
status: NEW122 A: 20 òe;g of membrane fraction from HEK293 cells transiently transfected with WT ABCA3-GFP (lanes 2 and 3) or with ABCA3-GFP mutants L101P (lanes 4 and 5), R295C (lanes 6 and 7), N568D (lanes 8 and 9), and L982P (lanes 10 and 11) were treated without (afa;) or with (af9;) endoglycosidase H (Endo H) and analyzed by 5% SDS-PAGE followed by immunoblotting with anti-GFP antibody. Lane 1, immunoblotting of untransfected HEK293 cells.
X
ABCA3 p.Asn568Asp 19861431:122:184
status: NEW123 B: WT ABCA3-GFP (lanes 2 and 3) or ABCA3-GFP mutants L101P (lanes 4 and 5), R295C (lanes 6 and 7), N568D (lanes 8 and 9), and L982P (lanes 10 and 11) were treated without (afa;) or with (af9;) peptide N-glycosidase F (PNGase F) and were then analyzed by 5% SDS-PAGE followed by immunoblotting with anti-GFP antibody. Lane 1, immunoblotting of untransfected HEK293 cells.
X
ABCA3 p.Asn568Asp 19861431:123:99
status: NEW[hide] ABC transporter A3 facilitates lysosomal sequestra... Haematologica. 2009 Nov;94(11):1528-36. Chapuy B, Panse M, Radunski U, Koch R, Wenzel D, Inagaki N, Haase D, Truemper L, Wulf GG
ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug.
Haematologica. 2009 Nov;94(11):1528-36., [PMID:19880777]
Abstract [show]
BACKGROUND: Inhibition of BCR-ABL tyrosine kinase activity has evolved as a mainstay of therapy for patients with chronic myeloid leukemia. However, a fraction of leukemic cells persists under targeted therapy and can lead to disease progression on cessation of treatment. DESIGN AND METHODS: We analyzed bone marrow progenitor cells with the side population phenotype, and characterized the role of the intracellular ABC transporter A3 in imatinib detoxification. RESULTS: BCR-ABL-positive leukemic cells contribute to the side population cell compartment in untreated patients. Such leukemic side population cells, as well as CD34-positive progenitors from chronic myeloid leukemia samples, strongly express the intracellular ABCA3. Functionally, ABCA3 levels are critical for the susceptibility of chronic myeloid leukemia blast cell lines to specific BCR-ABL inhibition by imatinib. The transporter is localized in the limiting membrane of lysosomes and multivesicular bodies, and intracellular [(14)C]-labeled imatinib accumulates in such organelles. The lysosomal storage capacity increases with ABCA3 expression, thus regulating imatinib sequestration. CONCLUSIONS: The intracellular ABC transporter A3 is expressed in chronic myeloid leukemia progenitor cells and may contribute to intrinsic imatinib resistance by facilitating lysosomal sequestration in chronic myeloid leukemia cells.
Comments [show]
None has been submitted yet.
No. Sentence Comment
32 Enforced expression and small interfering RNA of ABCA3 pEGFP-N1-ABCA3 wild-type or pEGFP-N1-ABCA3 N568D mutant plasmids16 as well as the pre-designed short interfering RNA (siRNA) against ABCA3 and scrambled siRNA (Qiagen) were delivered by electroporation as previously described.15 Using siRNA knock-down, the nadir of ABCA3 mRNA and ABCA3 protein expression was documented 72 h after electroporation, as tested by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) and western blotting (Online Supplementary Appendix Figures S2).
X
ABCA3 p.Asn568Asp 19880777:32:98
status: NEW91 normal BM non-SP SP Hoechst red Hoechstblu ABCA3abundance [foldofnon-SP] CML normal CD34+ CD34- CD34+ CD34- CML normal 0 100 250 500 1000 0 100 250 500 1000 0 100 250 500 10000 1 5 10 0 0.5 2.5 5 0 0.5 2.5 5 scrambled siRNAABCA3 siRNA scrambled siRNA ABCA3 siRNA Imatinib [µM] p-Crkl protein Imatinib [µM] Imatinib [µM] Imatinib[nM] Colonies[fractionofcontroll] Colonies[fractionofcontroll] Viability[fractionofcontroll] K562 K562 K562 LAMA84 LAMA84 BV173 LAMA84 Imatinib [µM] 0 1 5 10 ABCA3 siRNA scrambled siRNA ABCA3 siRNA scrambled siRNA ABCA3 siRNA scrambled siRNA ABCA3 siRNA scrambled siRNA ABCA3 siRNA scrambled siRNA ABCA3-N568D ABCA3-wt ABCA3-N568D ABCA3-wt 0 100 250 500 1000 0 100 250 500 1000 1 0.8 0.6 0.4 0.2 0 1 0.8 0.6 0.4 0.2 0 1 0.8 0.6 0.4 0.2 0 0 250 500 1 0.8 0.6 0.4 0.2 0 1 0.8 0.6 0.4 0.2 0 1 0.8 0.6 0.4 0.2 0 1 0.8 0.6 0.4 0.2 0 n=6 n=19 n=11 p=0.0255 0 1023 01023 ABCA3positive[%ofall] transcriptabundance 80 60 40 20 0 108 107 106 105 104 103 102 101 100 10-1 10-2 10-3 40 30 20 10 0 BC+AP CP BM CD34+ CD34- CML BM A A B C D B D C significantly increased the susceptibility of all three cell lines to the suppressive effects of imatinib.
X
ABCA3 p.Asn568Asp 19880777:91:652
status: NEWX
ABCA3 p.Asn568Asp 19880777:91:673
status: NEW106 B C D A -1 2 3 4 5 6 7 8 9 101112 131415 16171819 20 21 2223 35 30 25 20 15 10 5 0 35 30 25 20 15 10 5 0 25 20 15 10 5 0 25 20 15 10 5 0 1 2 3 4 5 6 7 8 9 101112 131415 16171819 20 21 2223 1 2 3 4 5 6 7 8 9 101112 131415 16171819 20 21 2223 β-Hexosaminidase [14 C]-Imatinib [%ofall][%ofall][%ofall] Activity[%ofall] Fraction LAMP1 EEA1 ABCA3-GFP NaKATPase HEK293 + ABCA3 HEK293 LAMA84 K562 Activity[%ofall]Activity[%ofall]Activity[%ofall] [14 C] Imatinib β-Hexosaminidase [14 C] Imatinib β-Hexosaminidase [14 C] Imatinib β-Hexosaminidase [14 C] Imatinib β-Hexosaminidase [%ofall] 100 80 60 40 20 0 100 80 60 40 20 0 100 80 60 40 20 0 100 80 60 40 20 0 [14 C]-Imatinib [14 C]-Imatinib Free Membrane bound Cytosol/Organelles Nucleus LL+ LL+ 1 2 3 4 5 6 7 8 9 101112 131415 16171819 20 21 2223 LAMA84 K562 HEK293-ABCA3 HEK293 HEK293-ABCA3 HEK293 HEK293-ABCA3 HEK293 with ectopic expression of wild-type ABCA3 and cells expressing the non-functional ABCA3-N568D variant carrying a mutation at the Walker A motif of the transporter (Figure 2C).
X
ABCA3 p.Asn568Asp 19880777:106:983
status: NEW92 normal BM non-SP SP Hoechst red Hoechst blu ABCA3 abundance [fold of non-SP] CML normal CD34+ CD34- CD34+ CD34- CML normal 0 100 250 500 1000 0 100 250 500 1000 0 100 250 500 1000 0 1 5 10 0 0.5 2.5 5 0 0.5 2.5 5 scrambled siRNA ABCA3 siRNA scrambled siRNA ABCA3 siRNA Imatinib [&#b5;M] p-Crkl protein Imatinib [&#b5;M] Imatinib [&#b5;M] Imatinib [nM] Colonies [fraction of controll] Colonies [fraction of controll] Viability [fraction of controll] K562 K562 K562 LAMA84 LAMA84 BV173 LAMA84 Imatinib [&#b5;M] 0 1 5 10 ABCA3 siRNA scrambled siRNA ABCA3 siRNA scrambled siRNA ABCA3 siRNA scrambled siRNA ABCA3 siRNA scrambled siRNA ABCA3 siRNA scrambled siRNA ABCA3-N568D ABCA3-wt ABCA3-N568D ABCA3-wt 0 100 250 500 1000 0 100 250 500 1000 1 0.8 0.6 0.4 0.2 0 1 0.8 0.6 0.4 0.2 0 1 0.8 0.6 0.4 0.2 0 0 250 500 1 0.8 0.6 0.4 0.2 0 1 0.8 0.6 0.4 0.2 0 1 0.8 0.6 0.4 0.2 0 1 0.8 0.6 0.4 0.2 0 n=6 n=19 n=11 p=0.0255 0 1023 0 1023 ABCA3 positive [% of all] transcript abundance 80 60 40 20 0 108 107 106 105 104 103 102 101 100 10-1 10-2 10-3 40 30 20 10 0 BC+AP CP BM CD34 + CD34 - CML BM A A B C D B D C significantly increased the susceptibility of all three cell lines to the suppressive effects of imatinib.
X
ABCA3 p.Asn568Asp 19880777:92:664
status: NEWX
ABCA3 p.Asn568Asp 19880777:92:685
status: NEW107 B C D A -1 2 3 4 5 6 7 8 9 101112 131415 16171819 20 21 2223 35 30 25 20 15 10 5 0 35 30 25 20 15 10 5 0 25 20 15 10 5 0 25 20 15 10 5 0 1 2 3 4 5 6 7 8 9 101112 131415 16171819 20 21 2223 1 2 3 4 5 6 7 8 9 101112 131415 16171819 20 21 2223 b2;-Hexosaminidase [14 C]-Imatinib [% of all] [% of all] [% of all] Activity [% of all] Fraction LAMP1 EEA1 ABCA3-GFP NaKATPase HEK293 + ABCA3 HEK293 LAMA84 K562 Activity [% of all] Activity [% of all] Activity [% of all] [14 C] Imatinib b2;-Hexosaminidase [14 C] Imatinib b2;-Hexosaminidase [14 C] Imatinib b2;-Hexosaminidase [14 C] Imatinib b2;-Hexosaminidase [% of all] 100 80 60 40 20 0 100 80 60 40 20 0 100 80 60 40 20 0 100 80 60 40 20 0 [14 C]-Imatinib [14 C]-Imatinib Free Membrane bound Cytosol/Organelles Nucleus LL+ LL+ 1 2 3 4 5 6 7 8 9 101112 131415 16171819 20 21 2223 LAMA84 K562 HEK293-ABCA3 HEK293 HEK293-ABCA3 HEK293 HEK293-ABCA3 HEK293 with ectopic expression of wild-type ABCA3 and cells expressing the non-functional ABCA3-N568D variant carrying a mutation at the Walker A motif of the transporter (Figure 2C).
X
ABCA3 p.Asn568Asp 19880777:107:1002
status: NEW[hide] Intracellular ABC transporter A3 confers multidrug... Leukemia. 2008 Aug;22(8):1576-86. Epub 2008 May 8. Chapuy B, Koch R, Radunski U, Corsham S, Cheong N, Inagaki N, Ban N, Wenzel D, Reinhardt D, Zapf A, Schweyer S, Kosari F, Klapper W, Truemper L, Wulf GG
Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration.
Leukemia. 2008 Aug;22(8):1576-86. Epub 2008 May 8., [PMID:18463677]
Abstract [show]
Multidrug resistance (MDR) seriously limits the efficacy of chemotherapy in patients with cancer and leukemia. Active transport across membranes is essential for such cellular drug resistance, largely provided by ATP-binding cassette (ABC) transport proteins. Intracellular drug sequestration contributes to MDR; however, a genuine intracellular ABC transport protein with MDR function has not yet been identified. Analyzing the intrinsic drug efflux capacity of leukemic stem cells, we found the ABC transporter A3 (ABCA3) to be expressed consistently in acute myeloid leukemia (AML) samples. Greater expression of ABCA3 is associated with unfavorable treatment outcome, and in vitro, elevated expression induces resistance toward a broad spectrum of cytostatic agents. ABCA3 remains localized within the limiting membranes of lysosomes and multivesicular bodies, in which cytostatics are efficiently sequestered. In addition to AML, we also detected ABCA3 in a panel of lymphohematopoietic tissues and transformed cell lines. In conclusion, we identified subcellular drug sequestration mediated by the genuinely intracellular ABCA3 as being a clinically relevant mechanism of intrinsic MDR.
Comments [show]
None has been submitted yet.
No. Sentence Comment
21 The pEGFP-N1-ABCA3 wild-type (wt) and pEGFP-N1-ABCA3 N568D mutant plasmids were described previously.10 The monoclonal mouse antibody to early endosomal antigen 1 (EEA1) was obtained commercially (Transduction Laboratories), the antibodies to lysosomal-associated membrane protein 1 (LAMP1, code H4A3) and LAMP2 (code H4B4) were from the Developmental Studies Hybridoma Bank (Iowa City, IA, USA).
X
ABCA3 p.Asn568Asp 18463677:21:53
status: NEW62 Oldendorf, Germany) with 10 mg of either pmax-GFP, pEGFP- N1-ABCA3 wt or pEGFP-N1-ABCA3 N568D, pulsed in an EasyjecT (Equi Bio, Middlesex, UK) electroporator (300 V, 1050 mF, 99 O, t: 104 ms) and incubated for 3 h in 400 ml OptiMEM before further expansion with 1.5 ml of complete growth medium overnight.
X
ABCA3 p.Asn568Asp 18463677:62:87
status: NEW139 A nonfunctional, mutated variant N568D-eGFP of ABCA3 does not induce drug resistance, and specific siRNA against ABCA3 increases the cytotoxic efficacy of DNR, etoposide and Ara-C (Supplementary Figure 2C, D).
X
ABCA3 p.Asn568Asp 18463677:139:33
status: NEW[hide] ABCA3-mediated choline-phospholipids uptake into i... FEBS Lett. 2007 Jul 10;581(17):3139-44. Epub 2007 Jun 6. Matsumura Y, Sakai H, Sasaki M, Ban N, Inagaki N
ABCA3-mediated choline-phospholipids uptake into intracellular vesicles in A549 cells.
FEBS Lett. 2007 Jul 10;581(17):3139-44. Epub 2007 Jun 6., [PMID:17574245]
Abstract [show]
ABCA3 is proposed to function as a lung surfactant lipid transporter. Here we report ABCA3-dependent lipid uptake into intracellular vesicles in lung adenocarcinoma A549 cells. A549 cells stably expressing GFP-tagged wild-type ABCA3 (A549/ABCA3(WT)) had larger LAMP3-positive vesicles than their parental cells as well as A549 cells expressing a Walker A motif mutant (A549/ABCA3(N568D)). The choline-phospholipids level in A549/ABCA3(WT) was increased 1.25-fold compared to that in A549 and A549/ABCA3(N568D) cells, while the cholesterol levels were similar. Sucrose gradient fractionation analysis in A549/ABCA3(WT) cells revealed that choline-phospholipids were enriched in low-density and nile red-positive vesicles. Electronmicroscopic analysis showed multilamellar vesicles in A549/ABCA3(WT) cells. These results indicate that ABCA3 mediates ATP-dependent choline-phospholipids uptake into intracellular vesicles.
Comments [show]
None has been submitted yet.
No. Sentence Comment
21 Establishment of stable cell line A549 cells stably expressing GFP-tagged Walker A motif mutant (N568D) ABCA3 protein (ABCA3-GFP) were established as previously described [10].
X
ABCA3 p.Asn568Asp 17574245:21:97
status: NEW54 Results 3.1. Expression of wild-type ABCA3-GFP enlarges LAMP3-positive vesicles in A549 cells We previously established lung adenocarcinoma A549/ABCA3WT cells, which stably express GFP-tagged wild-type Fig. 1. Expression of wild-type and N568D ABCA3-GFP in A549 cells.
X
ABCA3 p.Asn568Asp 17574245:54:238
status: NEW62 Similarly, GFP-tagged expression plasmid of ABCA3 containing naturally occurring mutation N568D in the Walker A motif, which exhibits impaired ATP-binding and ATP-hydrolysis activities [10], was transfected in A549 cells to generate A549/ABCA3N568D cells.
X
ABCA3 p.Asn568Asp 17574245:62:90
status: NEW104 Discussion In this study, to clarify the mechanism of lipid transport mediated by ABCA3, GFP-tagged wild-type and N568D mutant ABCA3, which exhibits impaired ATP-binding and ATP-hydrolysis activities [10], were stably expressed in A549 Fig. 3.
X
ABCA3 p.Asn568Asp 17574245:104:114
status: NEW55 Results 3.1. Expression of wild-type ABCA3-GFP enlarges LAMP3-positive vesicles in A549 cells We previously established lung adenocarcinoma A549/ABCA3WT cells, which stably express GFP-tagged wild-type Fig. 1. Expression of wild-type and N568D ABCA3-GFP in A549 cells.
X
ABCA3 p.Asn568Asp 17574245:55:238
status: NEW63 Similarly, GFP-tagged expression plasmid of ABCA3 containing naturally occurring mutation N568D in the Walker A motif, which exhibits impaired ATP-binding and ATP-hydrolysis activities [10], was transfected in A549 cells to generate A549/ABCA3N568D cells.
X
ABCA3 p.Asn568Asp 17574245:63:90
status: NEW105 Discussion In this study, to clarify the mechanism of lipid transport mediated by ABCA3, GFP-tagged wild-type and N568D mutant ABCA3, which exhibits impaired ATP-binding and ATP-hydrolysis activities [10], were stably expressed in A549 Fig. 3.
X
ABCA3 p.Asn568Asp 17574245:105:114
status: NEW[hide] Characterization and classification of ATP-binding... J Biol Chem. 2006 Nov 10;281(45):34503-14. Epub 2006 Sep 7. Matsumura Y, Ban N, Ueda K, Inagaki N
Characterization and classification of ATP-binding cassette transporter ABCA3 mutants in fatal surfactant deficiency.
J Biol Chem. 2006 Nov 10;281(45):34503-14. Epub 2006 Sep 7., [PMID:16959783]
Abstract [show]
The ATP-binding cassette transporter ABCA3 is expressed predominantly at the limiting membrane of the lamellar bodies in lung alveolar type II cells. Recent study has shown that mutation of the ABCA3 gene causes fatal surfactant deficiency in newborns. In this study, we investigated in HEK293 cells the intracellular localization and N-glycosylation of the ABCA3 mutants so far identified in fatal surfactant deficiency patients. Green fluorescent protein-tagged L101P, L982P, L1553P, Q1591P, and Ins1518fs/ter1519 mutant proteins remained localized in the endoplasmic reticulum, and processing of oligosaccharide was impaired, whereas wild-type and N568D, G1221S, and L1580P mutant ABCA3 proteins trafficked to the LAMP3-positive intracellular vesicle, accompanied by processing of oligosaccharide from high mannose type to complex type. Vanadate-induced nucleotide trapping and ATP-binding analyses showed that ATP hydrolysis activity was dramatically decreased in the N568D, G1221S, and L1580P mutants, accompanied by a moderate decrease in ATP binding in N568D and L1580P mutants but not in the G1221S mutant, compared with the wild-type ABCA3 protein. In addition, mutational analyses of the Gly-1221 residue in the 11th transmembrane segment and the Leu-1580 residue in the cytoplasmic tail, and homology modeling of nucleotide binding domain 2 demonstrate the significance of these residues for ATP hydrolysis and suggest a mechanism for impaired ATP hydrolysis in G1221S and L1580P mutants. Thus, surfactant deficiency because of ABCA3 gene mutation may be classified into two categories as follows: abnormal intracellular localization (type I) and normal intracellular localization with decreased ATP binding and/or ATP hydrolysis of the ABCA3 protein (type II). These distinct pathophysiologies may reflect both the severity and effective therapy for surfactant deficiency.
Comments [show]
None has been submitted yet.
No. Sentence Comment
3 Green fluorescent protein-tagged L101P, L982P, L1553P, Q1591P, and Ins1518fs/ter1519 mutant proteins remained localized in the endoplasmic reticulum, and processing of oligosaccharide was impaired, whereas wild-type and N568D, G1221S, and L1580P mutant ABCA3 proteins trafficked to the LAMP3-positive intracellular vesicle, accompanied by processing of oligosaccharide from high mannose type to complex type.
X
ABCA3 p.Asn568Asp 16959783:3:220
status: NEW4 Vanadate-induced nucleotide trapping and ATP-binding analyses showed that ATP hydrolysis activity was dramatically decreased in the N568D, G1221S, and L1580P mutants, accompanied by a moderate decrease in ATP binding in N568D and L1580P mutants but not in the G1221S mutant, compared with the wild-type ABCA3 protein.
X
ABCA3 p.Asn568Asp 16959783:4:132
status: NEWX
ABCA3 p.Asn568Asp 16959783:4:220
status: NEW35 Partial cDNA fragments containing various fatal surfactant deficiency mutations (L101P, N568D, L982P, G1221S, L1553P, L1580P, Q1591P, W1142X, and Ins1518fs (abbreviation of Ins1518fs/ter1519 in this study), see Fig. 1A), were generated with PCR methods and replaced with the corresponding fragment of pEGFPN1-ABCA3.
X
ABCA3 p.Asn568Asp 16959783:35:88
status: NEW98 To examine the effect of the mutations found in fatal surfactant deficiency patients on subcellular localization of ABCA3, wild-type and mutant ABCA3-GFP (seven missense mutations L101P, N568D, L982P, G1221S, L1553P, L1580P, and Q1591P, and one nonsense mutation, Ins1518fs) were transiently expressed in HEK293 cells (Fig. 1A).
X
ABCA3 p.Asn568Asp 16959783:98:187
status: NEW99 The N568D, G1221S, and L1580P mutant proteins were mainly localized to the LAMP3-positive intracellular vesicle membrane (Fig. 2B, panels a-c, d-f, and g-i), similar to wild-type ABCA3 protein (Fig. 2A, panels e-h).
X
ABCA3 p.Asn568Asp 16959783:99:4
status: NEW102 In another cell line, mouse lung epithelial MLE12 cells, transiently expressed GFP-tagged wild-type and N568D, G1221S, and L1580P mutant proteins were mainly localized at the intracellular vesicle membrane, whereas the L101P, L982P, L1553P, Q1591P, and Ins1518fs mutant proteins were mainly localized to the ER (data not shown), confirming defective intracellular sorting of L101P, L982P, L1553P, Q1591P, and Ins1518fs ABCA3 mutant proteins.
X
ABCA3 p.Asn568Asp 16959783:102:104
status: NEW105 In the N568D, G1221S, and L1580P mutant proteins, which were mainly localized to the intracellular vesicle membrane, both the 220-kDa noncleaved form and the 180-kDa cleaved form were detected, similar to wild-type protein (Fig. 3A).
X
ABCA3 p.Asn568Asp 16959783:105:7
status: NEW121 A merged image of panels i-k is shown in panel l. B, HEK293 cells transiently expressing mutant ABCA3-GFP proteins (panels a, d, g, and j) were processed for immunofluorescence labeling of LAMP3 (panels b, e, h, and k): N568D (panels a-c), G1221S (panels d-f), L1580P (panels g-i), and L101P (panels j-l).
X
ABCA3 p.Asn568Asp 16959783:121:220
status: NEW124 The scale bar represents 5 m. kDa wild-type ABCA3-GFP and the seven missense mutant (L101P, N568D, L982P, G1221S, L1553P, L1580P, and Q1591P) proteins to produce a 210-kDa deglycosylated protein (Fig. 3B).
X
ABCA3 p.Asn568Asp 16959783:124:101
status: NEWX
ABCA3 p.Asn568Asp 16959783:124:237
status: NEW128 In the N568D, G1221S, and L1580P mutant proteins, about 30-40% of the 220-kDa protein remained as Endo H-insensitive complex-type protein (Fig. 3, C and D, band I), indicating that processing of oligosaccharide from high mannose type to complex type is largely preserved in these mutants.
X
ABCA3 p.Asn568Asp 16959783:128:7
status: NEW131 These results indicate that the N568D, G1221S, and L1580P mutant proteins are mainly localized at the intracellular vesicle membrane accompanied by processing of oligosaccharide from high mannose type to complex type, whereas the four missense mutant (L101P, L982D, L1553P, and Q1591P) and one nonsense mutant (Ins1518fs) proteins remain localized at the ER, with impaired processing of oligosaccharide.
X
ABCA3 p.Asn568Asp 16959783:131:32
status: NEW132 ATP Hydrolysis of ABCA3-GFP and Mutants-To investigate the mechanism of loss of function of the N568D, G1221S, and L1580P mutant proteins that are trafficked to intracellular vesicles accompanied by processing of sugar chains as is wild-type ABCA3 protein, we examined ATP hydrolysis of wild-type ABCA3-GFP and the mutant proteins.
X
ABCA3 p.Asn568Asp 16959783:132:96
status: NEW143 Band I shows Endo H-insensitive 220-kDa ABCA3-GFP proteins (wild-type, N568D, L982P, and L1553P) containing complex-type sugar chains.
X
ABCA3 p.Asn568Asp 16959783:143:71
status: NEW148 *, p Ͻ 0.05; **, p Ͻ 0.005 versus wild type. N.S., not significant. Characterization and Classification of ABCA3 Mutants 34508 expressing wild-type or mutant (N568D, G1221S, and L1580P) ABCA3-GFP fusion proteins were established.
X
ABCA3 p.Asn568Asp 16959783:148:172
status: NEW152 In the N568D, G1221S, and L1580P mutant proteins, vanadate-induced nucleotide trapping was significantly decreased to 12, 33, and 9% of that of the wild-type protein, respectively (Fig. 4, A, lanes 5-10, and C).
X
ABCA3 p.Asn568Asp 16959783:152:7
status: NEW157 ATP Binding of ABCA3-GFP and Mutants-To clarify the mechanism of loss of ATP hydrolysis activity of the N568D, G1221S, and L1580P mutant proteins, we examined ATP binding of wild-type ABCA3-GFP and the mutant proteins.
X
ABCA3 p.Asn568Asp 16959783:157:104
status: NEW162 A, 20,000 ϫ g membrane fraction prepared from HEK293 cells stably expressing the wild-type (Wt) ABCA3-GFP (lanes 3 and 4), N568D (lanes 5 and 6), G1221S (lanes 7 and 8), L1580P (lanes 9 and 10), or untransfected HEK293 cells (lanes 1 and 2) was incubated with 10 M 8-azido-[␣- 32 P]ATP in the absence (-) or presence (ϩ) of 0.4 mM orthovanadate (Vi) and 3 mM MgCl2 for 10 min at 37 °C. Proteins were photoaffinity-labeled with UV irradiation after removal of unbound ATP, electrophoresed on SDS-PAGE (5%), and transferred to a PVDF membrane.
X
ABCA3 p.Asn568Asp 16959783:162:129
status: NEW170 A, 20,000 ϫ g membrane fraction prepared from HEK293 cells stably expressing wild-type (Wt) ABCA3-GFP, N568D, G1221S, L101P, or untransfected HEK293 cells was incubated with 20 M 8-azido-[␥-32 P]ATP and 3 mM MgCl2 for 10 min at 0 °C. Proteins were photoaffinity-labeled with UV irradiation, immunoprecipitated using anti-human ABCA3 antibody, electrophoresed on SDS-PAGE (5%), and transferred to a PVDF membrane.
X
ABCA3 p.Asn568Asp 16959783:170:109
status: NEW175 However, the levels of photoaffinity labeling of N568D and L1580P mutant proteins were moderately decreased to 60 and 54% of that of wild-type protein, respectively.
X
ABCA3 p.Asn568Asp 16959783:175:49
status: NEW177 These results suggest that decreased ATP binding contributes to impaired ATP hydrolysis in the N568D, L1580P, and L101P mutants but not in the G1221S mutant.
X
ABCA3 p.Asn568Asp 16959783:177:95
status: NEW226 In contrast, the N568D, G1221S, and L1580P mutant proteins were localized to intracellular vesicle membrane accompanied by processing of oligosaccharide from high mannose type to complex type as found in wild-type ABCA3 protein.
X
ABCA3 p.Asn568Asp 16959783:226:17
status: NEWX
ABCA3 p.Asn568Asp 16959783:226:121
status: NEW227 However, vanadate-induced nucleotide trapping analysis revealed ATP hydrolysis activity to be significantly decreased in N568D, G1221S, and L1580P mutant ABCA3 proteins compared with wild type.
X
ABCA3 p.Asn568Asp 16959783:227:121
status: NEW236 homozygous type II ABCA3 mutations have not been reported, patients with type I/type II compound heterozygous ABCA3 mutations (L982P/G1221S and Ins1518fs/L1580P) died of surfactant deficiency during the neonatal period, and the lamellar bodies of lung tissue from a patient with L982P/G1221S were reported to be smaller than those from normal lung tissue (12).
X
ABCA3 p.Asn568Asp 16959783:236:55
status: NEW238 Type II mutations lie in various locations as follows: N568D in the Walker A motif of NBD-1, G1221S in TM-11, and L1580P in NBD-2 (Fig. 1A), and all of these amino acids are conserved in the ABCA subfamily (Fig. 1, B-D).
X
ABCA3 p.Asn568Asp 16959783:238:55
status: NEW249 Characterization and Classification of ABCA3 Mutants 34512 from the crystal structure of other ABC transporters (40), both ATP binding and ATP hydrolysis activities should be impaired in the N568D mutant protein.
X
ABCA3 p.Asn568Asp 16959783:249:192
status: NEW271 It is possible that the E292V mutation causes less severe disruption of intracellular trafficking or ATP hydrolysis activity.
X
ABCA3 p.Asn568Asp 16959783:271:67
status: NEW273 Very recently, Cheong et al. (19) reported that L101P, G1221S, and N568D mutant proteins have the most severe, moderate, and the least severe trafficking and processing defects.
X
ABCA3 p.Asn568Asp 16959783:273:67
status: NEW274 In this study, the difference in degree of defect between N568D and G1221S mutant proteins is slight, if any.
X
ABCA3 p.Asn568Asp 16959783:274:58
status: NEWX
ABCA3 p.Asn568Asp 16959783:274:196
status: NEW276 With regard to the function of the ABCA3 mutant proteins, their findings indicating impaired co-localization of fluorescence-labeled phosphatidylcholine with ABCA3-positive vesicles in G1221S and N568D may well correlate with our findings indicating impaired ATP hydrolysis activities of these mutants.
X
ABCA3 p.Asn568Asp 16959783:276:196
status: NEW225 In contrast, the N568D, G1221S, and L1580P mutant proteins were localized to intracellular vesicle membrane accompanied by processing of oligosaccharide from high mannose type to complex type as found in wild-type ABCA3 protein.
X
ABCA3 p.Asn568Asp 16959783:225:17
status: NEW247 Characterization and Classification of ABCA3 Mutants 34512 from the crystal structure of other ABC transporters (40), both ATP binding and ATP hydrolysis activities should be impaired in the N568D mutant protein.
X
ABCA3 p.Asn568Asp 16959783:247:192
status: NEW272 In this study, the difference in degree of defect between N568D and G1221S mutant proteins is slight, if any.
X
ABCA3 p.Asn568Asp 16959783:272:58
status: NEW[hide] Functional and trafficking defects in ATP binding ... J Biol Chem. 2006 Apr 7;281(14):9791-800. Epub 2006 Jan 16. Cheong N, Madesh M, Gonzales LW, Zhao M, Yu K, Ballard PL, Shuman H
Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome.
J Biol Chem. 2006 Apr 7;281(14):9791-800. Epub 2006 Jan 16., [PMID:16415354]
Abstract [show]
Members of the ATP binding cassette (ABC) protein superfamily actively transport a wide range of substrates across cell and intracellular membranes. Mutations in ABCA3, a member of the ABCA subfamily with unknown function, lead to fatal respiratory distress syndrome (RDS) in the newborn. Using cultured human lung cells, we found that recombinant wild-type hABCA3 localized to membranes of both lysosomes and lamellar bodies, which are the intracellular storage organelles for surfactant. In contrast, hABCA3 with mutations linked to RDS failed to target to lysosomes and remained in the endoplasmic reticulum as unprocessed forms. Treatment of those cells with the chemical chaperone sodium 4-phenylbutyrate could partially restore trafficking of mutant ABCA3 to lamellar body-like structures. Expression of recombinant ABCA3 in non-lung human embryonic kidney 293 cells induced formation of lamellar body-like vesicles that contained lipids. Small interfering RNA knockdown of endogenous hABCA3 in differentiating human fetal lung alveolar type II cells resulted in abnormal, lamellar bodies comparable with those observed in vivo with mutant ABCA3. Silencing of ABCA3 expression also reduced vesicular uptake of surfactant lipids phosphatidylcholine, sphingomyelin, and cholesterol but not phosphatidylethanolamine. We conclude that ABCA3 is required for lysosomal loading of phosphatidylcholine and conversion of lysosomes to lamellar body-like structures.
Comments [show]
None has been submitted yet.
No. Sentence Comment
43 hABCA3 missense mutants (L101P, N568D, and G1221S) were generated using the PCR method with the following primers: L101P (forward primer, 5Ј-AGACAGTGCGCAGGGCACCTGTGATCAACATGCG- AG-3Ј; reverse primer, 5Ј-CTCGCATGTTGATCACAGGTGCCCT- GCGCACTGTCT-3Ј); N568D (forward primer, 5Ј-ATCACCGTCCT- GCTGGGCCACGACGGTGCCGGGAAGAC-3Ј; reverse primer, 5Ј- GTCTTCCCGGCACCGTCGTGGCCCAGCAGGACGGTGAT-3Ј); and G1221S (forward primer, 5Ј-ATCTTCAACATCCTGTCAGCCA- TCGCCACCTTCCTG-3Ј; reverse primer, 5Ј-CAGGAAGGTGGCG- AGGCCTGACAGGATGTTGAAGAT-3Ј), where the mutated nucleotides are underlined.
X
ABCA3 p.Asn568Asp 16415354:43:32
status: NEWX
ABCA3 p.Asn568Asp 16415354:43:271
status: NEW96 The first was in extracellular loop 1 (L101P), the second in the Walker A motif or P-loop (phosphate binding loop) of the N-terminal nucleotide binding domain (N568D), and the third in transmembrane domain 11 (G1221S) of hABCA3.
X
ABCA3 p.Asn568Asp 16415354:96:160
status: NEW101 The construct containing mutation N568D often localized to the lysosomal membrane (Fig. 2A, g-i) and partially remained in the ER (Fig. 2B, g-i).
X
ABCA3 p.Asn568Asp 16415354:101:34
status: NEW103 Western blotting with GFP antibody revealed that mutant protein is expressed at a lower overall level than wild-type protein and that wild-type and mutant fusion proteins (L101P, N568D, and G1221S) are processed differently (Fig. 2C).
X
ABCA3 p.Asn568Asp 16415354:103:179
status: NEW106 Densitometry analysis of a 180/220-kDa ratio of Western blot (Fig. 2C) was 0.85 for the wild-type protein, 0.45 for the N568D mutant, 0.3 for the G1221S mutant, and essentially 0.0 for the L101P mutant.
X
ABCA3 p.Asn568Asp 16415354:106:120
status: NEW117 LysoTracker Red (A) and ERTracker Red (B) staining of wild-type (a-c) and missense mutations of hABCA3 (L101P (d-f), N568D (g-i), and G1221S (j-l)) linked to GFP in transfected A549 cells.
X
ABCA3 p.Asn568Asp 16415354:117:117
status: NEW119 The wild-type, L101P, N568D, and G1221S hABCA3-GFP membrane fractions were incubated in the absence (-) or presence (ϩ) of 250 units of PNGase F at 37 °C for 1 h.
X
ABCA3 p.Asn568Asp 16415354:119:22
status: NEW161 Because N568D and G1221S hABCA3-GFP protein partially localized to the lysosomal membrane, we examined whether those lysosomes would take up NBD-lipid.
X
ABCA3 p.Asn568Asp 16415354:161:8
status: NEWX
ABCA3 p.Asn568Asp 16415354:161:39
status: NEW162 C12-NBD-PC did not colocalize with the N568D hABCA3-DsRed (Fig. 7B, a-c); however, a fraction of C12- NBD-PC colocalized with G1221S hABCA3-DsRed (Fig. 7B, d-f, arrows).
X
ABCA3 p.Asn568Asp 16415354:162:39
status: NEW197 The (N568D) mutant in the N-terminal P-loop of ABCA3 had the least severe trafficking defect but did not transport NBD-lipid.
X
ABCA3 p.Asn568Asp 16415354:197:5
status: NEW222 B, A549 cells with N568D (a-c) and G1221S (d-f) hABCA3-DsRed incubated with C12-NBD-PC-labeled liposomes.
X
ABCA3 p.Asn568Asp 16415354:222:19
status: NEW116 LysoTracker Red (A) and ERTracker Red (B) staining of wild-type (a-c) and missense mutations of hABCA3 (L101P (d-f), N568D (g-i), and G1221S (j-l)) linked to GFP in transfected A549 cells.
X
ABCA3 p.Asn568Asp 16415354:116:117
status: NEW118 The wild-type, L101P, N568D, and G1221S hABCA3-GFP membrane fractions were incubated in the absence (afa;) or presence (af9;) of 250 units of PNGase F at 37 &#b0;C for 1 h.
X
ABCA3 p.Asn568Asp 16415354:118:22
status: NEW160 Because N568D and G1221S hABCA3-GFP protein partially localized to the lysosomal membrane, we examined whether those lysosomes would take up NBD-lipid.
X
ABCA3 p.Asn568Asp 16415354:160:8
status: NEW196 The (N568D) mutant in the N-terminal P-loop of ABCA3 had the least severe trafficking defect but did not transport NBD-lipid.
X
ABCA3 p.Asn568Asp 16415354:196:5
status: NEW220 B, A549 cells with N568D (a-c) and G1221S (d-f) hABCA3-DsRed incubated with C12-NBD-PC-labeled liposomes.
X
ABCA3 p.Asn568Asp 16415354:220:19
status: NEW[hide] A large kindred of pulmonary fibrosis associated w... Respir Res. 2014 Apr 15;15:43. doi: 10.1186/1465-9921-15-43. Campo I, Zorzetto M, Mariani F, Kadija Z, Morbini P, Dore R, Kaltenborn E, Frixel S, Zarbock R, Liebisch G, Hegermann J, Wrede C, Griese M, Luisetti M
A large kindred of pulmonary fibrosis associated with a novel ABCA3 gene variant.
Respir Res. 2014 Apr 15;15:43. doi: 10.1186/1465-9921-15-43., [PMID:24730976]
Abstract [show]
BACKGROUND: Interstitial lung disease occurring in children is a condition characterized by high frequency of cases due to genetic aberrations of pulmonary surfactant homeostasis, that are also believed to be responsible of a fraction of familial pulmonary fibrosis. To our knowledge, ABCA3 gene was not previously reported as causative agent of fibrosis affecting both children and adults in the same kindred. METHODS: We investigated a large kindred in which two members, a girl whose interstitial lung disease was first recognized at age of 13, and an adult, showed a diffuse pulmonary fibrosis with marked differences in terms of morphology and imaging. An additional, asymptomatic family member was detected by genetic analysis. Surfactant abnormalities were investigated at biochemical, and genetic level, as well as by cell transfection experiments. RESULTS: Bronchoalveolar lavage fluid analysis of the patients revealed absence of surfactant protein C, whereas the gene sequence was normal. By contrast, sequence of the ABCA3 gene showed a novel homozygous G > A transition at nucleotide 2891, localized within exon 21, resulting in a glycine to aspartic acid change at codon 964. Interestingly, the lung specimens from the girl displayed a morphologic usual interstitial pneumonitis-like pattern, whereas the specimens from one of the two adult patients showed rather a non specific interstitial pneumonitis-like pattern. CONCLUSIONS: We have detected a large kindred with a novel ABCA3 mutation likely causing interstitial lung fibrosis affecting either young and adult family members. We suggest that ABCA3 gene should be considered in genetic testing in the occurrence of familial pulmonary fibrosis.
Comments [show]
None has been submitted yet.
No. Sentence Comment
273 In accordance with these results it was also shown previously that phosphatidylcholine accumulation in cells expressing ABCA3 with the walker A motif mutant N568D was diminished [27].
X
ABCA3 p.Asn568Asp 24730976:273:157
status: NEW[hide] Mutations in the ABCA3 gene are associated with ca... Invest Ophthalmol Vis Sci. 2014 Nov 18;55(12):8031-43. doi: 10.1167/iovs.14-14098. Chen P, Dai Y, Wu X, Wang Y, Sun S, Xiao J, Zhang Q, Guan L, Zhao X, Hao X, Wu R, Xie L
Mutations in the ABCA3 gene are associated with cataract-microcornea syndrome.
Invest Ophthalmol Vis Sci. 2014 Nov 18;55(12):8031-43. doi: 10.1167/iovs.14-14098., [PMID:25406294]
Abstract [show]
PURPOSE: Cataract-microcornea syndrome (CCMC) is an autosomal dominant inherited disease characterized by the association of congenital cataract and microcornea without any other systemic anomaly or dysmorphism. Although mutations of several genes have been shown to cause dominant CCMC, in many patients the causative gene has not yet been identified. Our aim was to identify the disease-associated gene in Chinese patients with CCMC. METHODS: The CCMC patients from two unrelated Chinese families and 26 sporadic patients were enrolled. All the patients were screened by Sanger sequencing with no identified mutations. Genetic variations were screened by whole-exome sequencing and then validated using Sanger sequencing. RESULTS: By sequencing the whole exome of three patients in a Chinese four-generation dominant CCMC family (Family A), three heterozygous missense mutation (c.115C>G, c.277G>A, and c.4393G>A) were identified in ATP-binding cassette protein A3 (ABCA3). At highly conserved positions, changes (c.115C>G and c.4393G>A) were predicted to have functional impacts and completely cosegregated with the phenotype. We further confirmed our finding by identifying another heterozygous missense mutation, c.2408C>T, in ABCA3 in an additional dominant CCMC family (Family B), which also cosegregated with the phenotype. Moreover, four heterozygous mutations, two missense mutations (c.4253A>T, c.2069A>T) and two splice site mutations (c.4053+2T>C, c.2765-1G>T) were identified from the sporadic patients. The ABCA3 protein was expressed in human lens capsule, choroid-retinal pigment epithelium and retinal pigment epithelial cells. CONCLUSIONS: Mutations in the human ABCA3 gene were associated with lethal respiratory distress. Our study showed, for the first time to our knowledge, that mutations in ABCA3 were associated with CCMC, warranting further investigations on the pathogenesis of this disorder.
Comments [show]
None has been submitted yet.
No. Sentence Comment
293 Genetic Variants Identified in ABCA3 in Patients With Surfactant Metabolism Dysfunction-3 (SMDP3) dbSNP rs# Cluster ID Codons Substitution Mutation Type Mutation Mode rs121909181 c.3426G>A W1142X Missense Homozygosity rs121909182 c.301T>C L101P Missense Homozygosity rs121909183 c.4657T>C L1553P Missense Homozygosity rs28936691 c.4772A>C Q1591P Missense Heterozygosity rs121909184 c.1702G>A N568D Missense Heterozygosity - c.4909&#fe;1G>A - Splice site Homozygosity rs121909185 c.977T>C L326P Missense Homozygosity 19.
X
ABCA3 p.Asn568Asp 25406294:293:392
status: NEW[hide] Lost after translation: insights from pulmonary su... Am J Physiol Lung Cell Mol Physiol. 2015 Sep 15;309(6):L507-25. doi: 10.1152/ajplung.00139.2015. Epub 2015 Jul 17. Mulugeta S, Nureki S, Beers MF
Lost after translation: insights from pulmonary surfactant for understanding the role of alveolar epithelial dysfunction and cellular quality control in fibrotic lung disease.
Am J Physiol Lung Cell Mol Physiol. 2015 Sep 15;309(6):L507-25. doi: 10.1152/ajplung.00139.2015. Epub 2015 Jul 17., [PMID:26186947]
Abstract [show]
Dating back nearly 35 years ago to the Witschi hypothesis, epithelial cell dysfunction and abnormal wound healing have reemerged as central concepts in the pathophysiology of idiopathic pulmonary fibrosis (IPF) in adults and in interstitial lung disease in children. Alveolar type 2 (AT2) cells represent a metabolically active compartment in the distal air spaces responsible for pulmonary surfactant biosynthesis and function as a progenitor population required for maintenance of alveolar integrity. Rare mutations in surfactant system components have provided new clues to understanding broader questions regarding the role of AT2 cell dysfunction in the pathophysiology of fibrotic lung diseases. Drawing on data generated from a variety of model systems expressing disease-related surfactant component mutations [surfactant proteins A and C (SP-A and SP-C); the lipid transporter ABCA3], this review will examine the concept of epithelial dysfunction in fibrotic lung disease, provide an update on AT2 cell and surfactant biology, summarize cellular responses to mutant surfactant components [including endoplasmic reticulum (ER) stress, mitochondrial dysfunction, and intrinsic apoptosis], and examine quality control pathways (unfolded protein response, the ubiquitin-proteasome system, macroautophagy) that can be utilized to restore AT2 homeostasis. This integrated response and its derangement will be placed in the context of cell stress and quality control signatures found in patients with familial or sporadic IPF as well as non-surfactant-related AT2 cell dysfunction syndromes associated with a fibrotic lung phenotype. Finally, the need for targeted therapeutic strategies for pulmonary fibrosis that address epithelial ER stress, its downstream signaling, and cell quality control are discussed.
Comments [show]
None has been submitted yet.
No. Sentence Comment
267 Summary of reported phenotypic features for surfactant component mutations Mutation (Domain) Clinical Diagnosis Lung Phenotype (in vivo) Subcellular Localization Trafficking Cellular Responses (in vitro) References SFTPA2 F198S (CRD) G231V (CRD) Familial pulmonary fibrosis Total BAL [SP-A] Normal ER retention Intracellular aggregation Not secreted (af9;) ER stress, cleared by ERAD (af9;) TGFbeta1 elaboration 99, 100, 175 SFTPC Group A1 èc;Exon4 (BRICHOS) L188Q (BRICHOS) G100S (BRICHOS) NSIP (Children) IPF/UIP (Adult) Absence of mature SP-C (humans) Arrested lung development (mice) ER stress (humans; mice) 1Sensitivity to bleomycin (mice) Epithelial cytotoxicity ER retention&#a1; aggresomes Intracellular aggregates ERAD requires Erdj 4/5 MG132 blocks degradation 4-PBA improves aggregates (af9;) ER stress (af9;) Apoptosis (af9;) Incomplete or absent proSP-C processing (af9;) IL-8/TGFbeta1 expression (af9;) Polyubiquitinated isoforms 21, 39, 97, 98, 100, 111, 112, 116, 117, 120, 153, 159, 160, 173, 193 Group A2 L110R (BRICHOS) P115L (BRICHOS) A116D (BRICHOS) Unspecified ILD Unspecified ILD Unspecified chILD Phenotype not reported EEA-1 (af9;); Syntaxin2 (afa;) Intracellular aggregation 2 PC secretion (af9;) Aberrant processing, 2 cell viability 1 HSP response (af9;) Congo red aggregates 160, 193 Group B1 E66K (Linker) I73T (Linker) NSIP/PAP (Child) IPF/UIP (Adult) 1 Phospholipid; 1SP-A, PAS positive staining Biopsy: PM and EE localization Misprocessed SP-C (BAL) Misprocessed SP-B (BAL) Plasma membrane&#a1;EE&#a1;LE/MVB (af9;) Aberrantly processed protein (af9;) Late autophagy block 2 Mitophagy 1 Mysfunctional mitochondria 1, 19, 24, 26, 49, 116, 118, 128, 152 Group B2 èc;91-93 (Non-BRICHOS) NSIP/PAP 2 BAL SP-B 1 BAL SP-A 2 Surfactant surface tension (af9;) Intracellular aggregates (af9;) Congo red staining Plasma membraneߥ EEA1 (af9;) compartmentsߥ Not reported 55, 181 Group C P30L (NH2-terminal) Unspecified ILD Phenotype not reported (af9;) ER retention 1 Bip expression (af9;) Polyubiquitinated isoforms 13, 116, 160 ABCA3 Group I (Trafficking Defective) L101P (1st luminal loop) R280C (1st cytosolic loop) L982P (3rd luminal loop) G1221S (11th TM domain) L1553P (COOH-terminal) Q1591P (COOH-terminal) Surfactant deficiency* RDS* chILDߤ Phenotype not reported Phenotype not reported Phenotype not reported (af9;) ER retention Non-LRO cytosolic vesicles (af9;) ER stress 30, 31, 103, 147, 172, 177 Group II (Functionally Defective) R43L (1st luminal loop) D253H (1st luminal loop) E292V (1st cytosolic loop) N568D (ABC1) E690K (ABC1) T1114M (8thTM domain) T1173R (1st luminal loop) L1580P (COOH-terminal) Surfactant deficiency* RDS* chILD (CPI)ߤ Reduced SP-B and SP-C (afa;) ER retention Lysosomes or LROs (normal) Impaired lipid transport Impaired ATP hydrolysis Impaired ATP binding Abnormal LBs 1 IL8 secretion 20, 25, 103, 104, 147, 148, 177 *Seen with homozygous or compound heterozygous ABCA3 expression; ߤfound with heterozugous ABCA3 expression.
X
ABCA3 p.Asn568Asp 26186947:267:2626
status: NEW[hide] Structural Features of the ATP-Binding Cassette (A... Int J Mol Sci. 2015 Aug 19;16(8):19631-44. doi: 10.3390/ijms160819631. Paolini A, Baldassarre A, Del Gaudio I, Masotti A
Structural Features of the ATP-Binding Cassette (ABC) Transporter ABCA3.
Int J Mol Sci. 2015 Aug 19;16(8):19631-44. doi: 10.3390/ijms160819631., [PMID:26295388]
Abstract [show]
In this review we reported and discussed the structural features of the ATP-Binding Cassette (ABC) transporter ABCA3 and how the use of bioinformatics tools could help researchers to obtain a reliable structural model of this important transporter. In fact, a model of ABCA3 is still lacking and no crystallographic structures (of the transporter or of its orthologues) are available. With the advent of next generation sequencing, many disease-causing mutations have been discovered and many more will be found in the future. In the last few years, ABCA3 mutations have been reported to have important pediatric implications. Thus, clinicians need a reliable structure to locate relevant mutations of this transporter and make genotype/phenotype correlations of patients affected by ABCA3-related diseases. In conclusion, we strongly believe that the model preliminarily generated by these novel bioinformatics tools could be the starting point to obtain more refined models of the ABCA3 transporter.
Comments [show]
None has been submitted yet.
No. Sentence Comment
49 One of these in vitro studies demonstrated that the p.N568D mutation in ABCA3 impairs choline-phospholipids uptake into intracellular vesicles in lung adenocarcinoma A549 cells [25] and primary AT2 cells [26].
X
ABCA3 p.Asn568Asp 26295388:49:54
status: NEW50 Moreover, in WT cells` ultrastructural images confirmed the regular formation of lamellar bodies, whereas in the p.N568D mutant the formation of these multilamellar vesicles has not been observed.
X
ABCA3 p.Asn568Asp 26295388:50:118
status: NEW